| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 24, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the first patient was enrolled in the FIRE AND ICE clinical trial, which is a prospective, randomized,...
-
Nov 4, 2011Presentations Cover Stents and Balloons for Coronary and Peripheral Artery Disease, Transcatheter Valve for Aortic Stenosis, Stent Grafts for Aortic Aneurysms, and Renal Denervation for Treatment-Resistant Hypertension and Heart Failure
MINNEAPOLIS, Nov 04, 2011 (BUSINESS WIRE) -- Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT)...
-
Oct 27, 2011
MINNEAPOLIS, Oct 27, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration's (FDA) Circulatory Systems Devices advisory panel voted against...
-
Oct 10, 2011First Ever Randomized, Controlled Clinical Trial in Persistent Atrial Fibrillation (AF) Patients
VENICE, Italy & MINNEAPOLIS, Oct 10, 2011 (BUSINESS WIRE) -- Medtronic, Inc.(NYSE: MDT) today announced results from its Tailored Treatment of Permanent Atrial Fibrillation (TTOP-AF) clinical...
-
May 5, 2011
MINNEAPOLIS & SAN FRANCISCO, May 05, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced findings from the DISCERN AF trial, which utilized Medtronic's Reveal(R) XT insertable...